Kansas Cancer Center Offers One-Time Blood Cancer Treatment

Imagine beating cancer with a single treatment instead of weekly clinic visits for the rest of your life.

The Kansas University Cancer Center now offers CAR T-cell therapy, a revolutionary approach for blood cancer patients that could end the exhausting cycle of ongoing chemotherapy and radiation. Dr. Joseph McGuirk leads the program, which takes patients' own T-cells and genetically reprograms them to attack cancer.

The treatment shows particular promise for multiple myeloma patients. "Most of these patients continue treatment for the rest of their life," explains Dr. Al-Ola Abdallah, director of plasma cell disorders care at The University of Kansas Health System. "Either they die from the disease or they cannot tolerate the treatment."

CAR T-cell therapy changes that equation completely. After the one-time treatment sends their cancer into remission, patients can step away from the endless medical appointments. "You don't have to come to the clinic every week to get any injection or infusion," Abdallah says. "You can enjoy your life."

The Ripple Effect

This advancement matters beyond individual patients. McGuirk and his team continue researching how CAR T-cells could treat solid tumors, not just blood cancers. They're also exploring whether T-cells from one person could treat another patient's cancer, which could make the therapy faster and more accessible.

Right now, many eligible patients never receive CAR T-cell therapy. McGuirk points to awareness gaps, accessibility challenges, and the specialized care required after treatment as barriers his team hopes to overcome.

Kansas patients now have access to a treatment that just years ago existed only in research labs. The therapy represents a fundamental shift from managing cancer as a chronic disease to potentially curing it with a single intervention.

One treatment could mean freedom from endless appointments and a return to normal life.